BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

903 related articles for article (PubMed ID: 16005483)

  • 21. [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report].
    Minenna G; D'Amore S; Maggiolini P; Scagliusi P; D'Amore M
    Recenti Prog Med; 2005 Sep; 96(9):431-2. PubMed ID: 16229324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.
    Hofbauer LC; Shui C; Riggs BL; Dunstan CR; Spelsberg TC; O'Brien T; Khosla S
    Biochem Biophys Res Commun; 2001 Jan; 280(1):334-9. PubMed ID: 11162519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
    Wada N; Maeda H; Yoshimine Y; Akamine A
    Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
    Padagas J; Colloton M; Shalhoub V; Kostenuik P; Morony S; Munyakazi L; Guo M; Gianneschi D; Shatzen E; Geng Z; Tan HL; Dunstan C; Lacey D; Martin D
    Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
    Humphrey EL; Williams JH; Davie MW; Marshall MJ
    Bone; 2006 May; 38(5):652-61. PubMed ID: 16298558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
    Cao J; Venton L; Sakata T; Halloran BP
    J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
    Ueland T; Yndestad A; Øie E; Florholmen G; Halvorsen B; Frøland SS; Simonsen S; Christensen G; Gullestad L; Aukrust P
    Circulation; 2005 May; 111(19):2461-8. PubMed ID: 15883214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronology and regulation of gene expression of RANKL in the rat dental follicle.
    Liu D; Yao S; Pan F; Wise GE
    Eur J Oral Sci; 2005 Oct; 113(5):404-9. PubMed ID: 16202028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization.
    Sandberg WJ; Yndestad A; Øie E; Smith C; Ueland T; Ovchinnikova O; Robertson AK; Müller F; Semb AG; Scholz H; Andreassen AK; Gullestad L; Damås JK; Frøland SS; Hansson GK; Halvorsen B; Aukrust P
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):857-63. PubMed ID: 16424351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse.
    Mori H; Kitazawa R; Mizuki S; Nose M; Maeda S; Kitazawa S
    Histochem Cell Biol; 2002 Mar; 117(3):283-92. PubMed ID: 11914926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The OPG/RANKL/RANK system in metabolic bone diseases.
    Hofbauer LC; Kühne CA; Viereck V
    J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):268-75. PubMed ID: 15615494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
    Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
    J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women.
    Messalli EM; Mainini G; Scaffa C; Cafiero A; Salzillo PL; Ragucci A; Cobellis L
    Maturitas; 2007 Jan; 56(1):38-44. PubMed ID: 16787719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
    Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
    Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
    Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint.
    Carda C; Silvestrini G; Gomez de Ferraris ME; Peydró A; Bonucci E
    Tissue Cell; 2005 Jun; 37(3):247-55. PubMed ID: 15899507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor.
    Yamada N; Tsujimura T; Ueda H; Hayashi S; Ohyama H; Okamura H; Terada N
    Cytokine; 2005 Aug; 31(4):288-97. PubMed ID: 15996478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.